Cryptogenic organizing pneumonia. Characteristics of relapses in a series of 48 patients. The Groupe d'Etudes et de Recherche sur les Maladles "Orphelines" Pulmonaires (GERM"O"P)

Détails

ID Serval
serval:BIB_7B3EB780AA58
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Cryptogenic organizing pneumonia. Characteristics of relapses in a series of 48 patients. The Groupe d'Etudes et de Recherche sur les Maladles "Orphelines" Pulmonaires (GERM"O"P)
Périodique
American Journal of Respiratory and Critical Care Medicine
Auteur⸱e⸱s
Lazor  R., Vandevenne  A., Pelletier  A., Leclerc  P., Court-Fortune  I., Cordier  J. F.
ISSN
1073-449X
Statut éditorial
Publié
Date de publication
08/2000
Peer-reviewed
Oui
Volume
162
Numéro
2 Pt 1
Pages
571-7
Notes
Journal Article
Research Support, Non-U.S. Gov't
Résumé
Cryptogenic organizing pneumonia (COP) is a clinicopathologic syndrome characterized by rapid resolution with corticosteroids, but frequent relapses when treatment is tapered or stopped. We retrospectively studied relapses in 48 cases of biopsy-proven COP. One or more relapses (mean 2.4 +/- 2.2) occurred in 58%. At first relapse, 68% of patients were still under treatment for the initial episode. Compared with the no-relapse group, nine patients with multiple (>/= 3) relapses had longer delays between first symptoms and treatment onset (22 +/- 17 versus 11 +/- 8 wk, p = 0.02), and elevated gamma-glutamyltransferase (124 +/- 98 versus 29 +/- 13 IU/L, p = 0.001) and alkaline phosphatase (190 +/- 124 versus 110 +/- 68 IU/L, p = 0.04) levels. Relapses did not adversely affect outcome. Corticosteroid treatment side effects occurred in 25% of patients. Standardized treatment in 14 patients allowed a reduction of prednisone cumulated doses (p < 0.05) without affecting outcome or relapse rate. We conclude that: (1) delayed treatment increases the risk of relapses; (2) mild cholestasis identifies a subgroup of patients with multiple relapses; (3) relapses do not affect outcome, and prolonged therapy to suppress relapses appears unnecessary; (4) a standardized treatment allows a reduction in steroid doses.
Mots-clé
Adult Aged Alkaline Phosphatase/blood Bronchiolitis Obliterans Organizing Pneumonia/drug therapy/mortality/*physiopathology Cholestasis/complications Female Humans Male Middle Aged Prednisone/adverse effects/therapeutic use Probability Recurrence Retrospective Studies Treatment Outcome gamma-Glutamyltransferase/blood
Pubmed
Web of science
Création de la notice
19/12/2008 12:59
Dernière modification de la notice
20/08/2019 15:37
Données d'usage